Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Taiwan / NCT07034521
Recruiting Not applicable

The Feasibility and Therapeutic Effect of Hybrid End-effector Robot-assisted Gait Training With an Active-assisted Module in Chronic Stroke Survivors

NCT07034521 · tracked via the Priya Life Science Taiwan tracker
Phase
Not applicable
Started
2025-08-12
Last updated
2026-05-19

Condition(s) studied

StrokeRehabilitationRobotic Rehabilitation

Investigational drug(s) / intervention(s)

HIWIN MRG-P110

HIWIN MRG-P110: HIWIN MRG-P110 is a robotics for lower limbs rehabilitation

Study summary

Walking rehabilitation after stroke is most effective during the first three months of recovery, but even in the chronic phase-beyond six months post-stroke-a significant number of patients still show potential for gait improvement. Robot-assisted rehabilitation is becoming increasingly common in clinical settings, with various design modes available. However, the effectiveness of new products in improving gait or motor function still requires further investigation.

This study aims to evaluate the usability and therapeutic effects of a new end-effector exoskeleton robot system, HIWIN MRG-P110, for gait training in chronic stroke patients. The system uses foot pedal mechanisms to drive hip and knee movements for lower-limb training. Unlike its predecessor, this device allows adjustment of the active assistance ratio, encouraging users to engage in voluntary movement. It is designed for gait training in stroke patients and others with neurological impairments, but the usability and efficacy of this new training model remain to be verified.

This clinical trial is a randomized, single-blind, prospective study enrolling 60 stroke patients who are 6 months to 3 years post-onset and have a Functional Ambulation Category (FAC) level of 0 to 3. The study will explore how patients with varying degrees of motor weakness learn to adapt to the "active-assistive mode" in terms of speed and perception. Participants will be randomly assigned to either the active-assistive mode group or the fully passive mode group. Both groups will receive 15 treatment sessions over 5 weeks.

The study will compare the two groups in terms of:

1. Improvements in gait and balance immediately post-treatment and at 3-month follow-up
2. Changes in brain activity, as measured by functional near-infrared spectroscopy (fNIRS)

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Aged between 18 and 80 years old. * First-ever stroke, confirmed by brain CT or MRI, with onset between 6 months and 3 years prior to enrollment. * Walking ability classified as Functional Ambulation Category (FAC) level 1 to level 3. * Prior to the current stroke, the participant was an independent community ambulator without mobility impairments. Exclusion Criteria: * Presence of lower limb joint contractures, deformities, or severe spasticity (Modified Ashworth Scale score of 4). * Lower limb musculoskeletal conditions causing wounds, pain, inability to bear weight, or significant leg length discrepancy (\>2 cm after orthotic correction). * Known history of osteoporotic fractures in the thoracolumbar spine or hip joints. * Inability to use the exoskeleton device due to body size, including: Body weight \> 135 kg; Thigh length \< 36 cm or \> 48 cm; Calf length \< 42 cm or \> 58 cm * Cognitive or communication impairments that prevent understanding of study instructions or completion of questionnaires. * Acute infections or unstable vital signs. * Significant orthostatic hypotension or inability to maintain upright posture for more than 30 minutes. * Use of indwelling urinary catheter or tracheostomy. * Pregnant women. * Terminal illness with life expectancy less than six months. * Inability to attend 15 rehabilitation sessions and follow-up assessment at 3 months.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
National Taiwan University Hospital Taipei Taipei Recruiting

More National Taiwan University Hospital trials in Taiwan

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07034521 on ClinicalTrials.gov ↗ ← All trials in Taiwan